NephRx Corp. Awarded U.S. Patent for NX002 for Treatment of Oral Mucositis
November 30, 2011 07:30 ET
|
NephRx Corporation
Second Patent Highlights Potential Broad Utility of Novel Growth Factor Peptide NX002 for Treatment of Oral Mucositis and Other GI Disorders
Initiation of Detailed Toxicology Studies Targeted for...